- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02254109
Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Rising of BEA 2180 BR in Japanese Healthy Male Volunteers
September 30, 2014 updated by: Boehringer Ingelheim
A Randomised, Double-blind, Placebo-controlled (Within Dose Groups) Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Rising Inhalative Doses (50 μg, 100 μg and 200 μg q.d. for 14 Days) of BEA 2180 BR in Japanese Healthy Male Volunteers
Study to evaluate safety, tolerability, and pharmacokinetics of BEA 2180 BR in Japanese healthy volunteers
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 35 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
Healthy Japanese men:
According to the results of a complete medical history, the physical examination, vital signs (blood pressure and pulse rate), 12-lead ECG, clinical laboratory tests
- Age ≥20 and ≤35 years
- Body mass index (BMI) ≥18.5 and ≤25 kg/m2
- Subjects must be able to inhale medication in a competent manner from the Respimat®
- Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP)
Exclusion Criteria:
- Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance
- Any evidence of a clinically relevant concomitant disease
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- Surgery of the gastrointestinal tract (except appendectomy)
- Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- History of relevant orthostatic hypotension, fainting spells or blackouts
- Chronic or relevant acute infections
- History of relevant allergy/hypersensitivity including allergy to drug or its excipients
- Intake of drugs with a long half-life (>24 hours) within one month or less than 10 half-lives of the respective drug before drug administration or during the trial
- Use of prescription or non-prescription drugs within 10 days before drug Administration or during the trial. However, over-the-counter (OTC) drugs for external application (such as lubricant eye drops for contact lens, insect bite reliever) shall be allowed
- Participation in another trial with an investigational drug within four months before drug administration or during the trial
- Smoker (>10 cigarettes or >3 cigars or >3 pipes/day)
- Inability to refrain from smoking during the trial
- Alcohol abuse (≥60 g/day: corresponds to ca. 3 large bottles of beer, 3 gous (ca. 540 cc) of Japanese sake, 6 shots of whisky, 6 glasses of wine or 6 glasses of Japanese shochu, distilled alcoholic beverage)
- Drug abuse
- Blood donation (≥100 mL within four weeks before drug administration or during the trial)
- Excessive physical activities (within one week before drug administration or during the trial)
- Any laboratory value outside the reference range that is of clinical relevance
Inability to comply with dietary regimen of trial site
Exclusion criteria specific for this study:
- Occupational (professional) exposure to antimuscarinic substances (e.g., physician, nurse, pharmacist etc.; volunteers working for medical institutions, research institutions or herb gardens)
- History of glaucoma, urination difficulty (due to prostatic hyperplasia etc.)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
|
Experimental: BEA 2180 BR - rising dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of subjects with abnormal findings in physical examination
Time Frame: up to 28 days after last dose administration
|
up to 28 days after last dose administration
|
|
Number of subjects with clinically significant changes in vital signs
Time Frame: up to 28 days after last dose administration
|
Blood pressure and pulse rate
|
up to 28 days after last dose administration
|
Number of subjects with clinically significant changes in 12-lead electrocardiogram (ECG)
Time Frame: up to 28 days after last dose administration
|
up to 28 days after last dose administration
|
|
Number of subjects with abnormal changes in laboratory parameters
Time Frame: up to 28 days after last dose administration
|
up to 28 days after last dose administration
|
|
Number of subjects with adverse events
Time Frame: up to 28 days after last dose administration
|
up to 28 days after last dose administration
|
|
Assessment of tolerability by the investigator on a 4-point scale
Time Frame: 28 days after last dose administration
|
28 days after last dose administration
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cmax (maximum measured concentration of the analyte in plasma)
Time Frame: up to 648:00 hours
|
up to 648:00 hours
|
tmax (time from dosing to maximum measured concentration of the analyte in plasma)
Time Frame: up to 648:00 hours
|
up to 648:00 hours
|
AUCτ (area under the concentration-time curve of the analyte in plasma over a uniform dosing interval τ)
Time Frame: up to 648:00 hours
|
up to 648:00 hours
|
AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable concentration at tz)
Time Frame: up to 648:00 hours
|
up to 648:00 hours
|
Aeτ (amount of analyte that is eliminated in urine over a uniform dosing interval τ)
Time Frame: up to 648:00 hours
|
up to 648:00 hours
|
feτ (fraction of analyte eliminated in urine over a uniform dosing interval τ)
Time Frame: up to 648:00 hours
|
up to 648:00 hours
|
CLR,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2)
Time Frame: up to 648:00 hours
|
up to 648:00 hours
|
Cmin,ss (minimum concentration of the analyte in plasma at steady state)
Time Frame: up to 648:00 hours
|
up to 648:00 hours
|
Cpre,ss (predose concentration of the analyte in plasma at steady state immediately before administration of the next dose)
Time Frame: up to 648:00 hours
|
up to 648:00 hours
|
λz,ss (terminal rate constant in plasma at steady state)
Time Frame: up to 648:00 hours
|
up to 648:00 hours
|
t1/2,ss (terminal half-life of the analyte in plasma at steady state)
Time Frame: up to 648:00 hours
|
up to 648:00 hours
|
MRTih,ss (mean residence time of the analyte in the body at steady state after inhalation administration)
Time Frame: up to 648:00 hours
|
up to 648:00 hours
|
CL/F,ss (apparent clearance of the analyte in the plasma at steady state following extravascular multiple dose administration)
Time Frame: up to 648:00 hours
|
up to 648:00 hours
|
Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following extravascular administration)
Time Frame: up to 648:00 hours
|
up to 648:00 hours
|
Accumulation ratio of the analyte in plasma based on Cmax (RA,Cmax)
Time Frame: up to 648:00 hours
|
up to 648:00 hours
|
Accumulation ratio of the analyte in plasma based on AUC (RA,AUC)
Time Frame: up to 648:00 hours
|
up to 648:00 hours
|
Accumulation ratio of the analyte in plasma based on Ae (RA,Ae)
Time Frame: up to 648:00 hours
|
up to 648:00 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2008
Primary Completion (Actual)
October 1, 2008
Study Registration Dates
First Submitted
September 30, 2014
First Submitted That Met QC Criteria
September 30, 2014
First Posted (Estimate)
October 1, 2014
Study Record Updates
Last Update Posted (Estimate)
October 1, 2014
Last Update Submitted That Met QC Criteria
September 30, 2014
Last Verified
September 1, 2014
More Information
Terms related to this study
Other Study ID Numbers
- 1205.18
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States